Light-guided therapy to help chemo and immunotherapy work better for pancreatic cancer
Molecular Imaging Guidance for Potentiating Chemoimmunotherapy in Pancreatic Cancer using Photodynamic Priming
Combines a harmless, light-activated treatment with imaging to help chemotherapy and immunotherapy reach and shrink pancreatic tumors for people with advanced disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project ID | NIH-11324626 on NIH RePORTER |
What this research studies
This research uses photodynamic priming, a light-activated approach, to loosen the dense tissue around pancreatic tumors so drugs can penetrate better. Molecular imaging will be used to guide where and when the light treatment is applied and to monitor how well the tumor is responding. The team will test the approach in laboratory 3D tumor models and animal studies and use imaging data to optimize combining photodynamic priming with existing chemo-immunotherapy regimens. If promising, the work is intended to enable future clinical testing that could include patient samples or trials at collaborating centers.
Who could benefit from this research
Good fit: People with pancreatic ductal adenocarcinoma, especially those with locally advanced or metastatic tumors who are receiving or eligible for chemo-immunotherapy, would be the main candidates for future clinical steps.
Not a fit: Patients with unrelated cancers, those with early-stage resectable pancreatic cancer who do not need systemic chemo-immunotherapy, or people unable to undergo light-based procedures may not benefit from this approach.
Why it matters
Potential benefit: If successful, the method could increase how well chemo-immunotherapy reaches pancreatic tumors and improve response rates and outcomes for patients with advanced pancreatic cancer.
How similar studies have performed: Early laboratory and animal studies show photodynamic priming can improve drug delivery, but clinical benefit in pancreatic cancer remains experimental and not yet established.
Where this research is happening
Richardson, United States
- University of Texas Dallas — Richardson, United States (Active)
Researchers
- Principal investigator: Obaid, Girgis — University of Texas Dallas
- Study coordinator: Obaid, Girgis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.